# Measurement of Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Liver Transplant Recipients

> **NCT00405652** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 34 (actual)

## Conditions studied

- Liver Transplantation

## Interventions

- **DRUG:** Enteric-coated Mycophenolate sodium (EC-MPS)

## Key facts

- **NCT ID:** NCT00405652
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2011-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00405652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00405652, "Measurement of Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Liver Transplant Recipients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00405652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*